Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eton Pharmaceuticals

Composite Rating For Eton Pharmaceuticals Rises To 96

Eton Pharmaceuticals saw an improvement in its IBD SmartSelect Composite Rating Friday, from 94 to 96.

Investors Business Daily

Eton Pharmaceuticals Sees Composite Rating Move Up To 96

Eton Pharmaceuticals Sees Composite Rating Move Up To 96

Eton Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 93 the day before.

Investors Business Daily

Eton Pharma - Small Cap That's Climbing

Eton Pharma - Small Cap That's Climbing

Summary Eton Pharmaceuticals (ETON) has shown exceptional price appreciation, gaining 224.93% since a Trend Seeker buy signal on 7/17, supported by strong technical indicators. The company focuses on developing and commercializing pharmaceutical products for rare diseases, with significant revenue and earnings growth expected in the coming years. Barchart's technical indicators...

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Pharma Stocks for January 2024 Profits

The pharmaceutical industry is thriving, fueled by steady demand for drugs, cost-efficient alternative discoveries, and rapid technological innovations. Hence, fundamentally strong pharma stocks Novo Nordisk (NVO), Eton Pharmaceuticals (ETON), and Pacira BioSciences (PCRX) might be profitable buys now. Read on….

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Earnings Outlook For Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Eton Pharmaceuticals will report an earnings per share (EPS) of $-0.08.

inkl

Read news from The Economist, FT, and more,
with one subscription

Eton Pharmaceuticals Names James Gruber Finance Chief

Eton Pharmaceuticals Names James Gruber Finance Chief

Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through May to ensure a smooth transition. Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw…

Organisations

Abbott Laboratories

Medical Pharmaceuticals

Novo Nordisk AS

Apellis Pharmaceuticals

Pacira Biosciences

Ultragenyx Pharmaceutical

Community Health Systems

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

295,283 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play